Jiangsu Hengrui Pharmaceuticals (01276): Atezolizumab injection obtains notification of approval for drug clinical trials.

Jiangsu Hengrui Pharmaceuticals (01276) announced that its subsidiary Shanghai Shengdi Pharmaceutical Co., Ltd. has recently received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for Atezolizumab Injection, and will soon begin clinical trials. Atezolizumab Injection is a humanized anti-PD-L1 monoclonal antibody independently developed by the company, which can block the PD-1/PD-L1 pathway that causes tumor immune tolerance by specifically binding to the PD-L1 molecule, reactivating the immune system's anti-tumor activity, and achieving the goal of treating tumors. The company's Atezolizumab Injection has been approved for marketing in 2023, with approved indications for first-line treatment in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer. Similar products such as Atezolizumab (brand name: Tecentriq), Avelumab (brand name: Bavencio), and Durvalumab (brand name: Imfinzi) have been approved for marketing in the United States, with Atezolizumab and Durvalumab also approved in China. Several similar products have been approved for marketing domestically. According to reports, the global sales of Atezolizumab, Avelumab, and Durvalumab in 2024 totaled approximately $9.648 billion. As of now, the total research and development investment in Atezolizumab Injection related projects is approximately 1,151.4 million RMB (unaudited).